Sun Pharmaceutical has received a significant approval from the USFDA. The company's innovative drug, Ilumya, is now being considered for treating adults with active psoriatic arthritis. This marks a crucial step for Sun Pharma in expanding its medicine portfolio. The US regulator has accepted the application for review.